GUTS (Fractyl Health) EBIT per Share : $-1.97 (TTM As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Fractyl Health EBIT per Share?

Fractyl Health's EBIT per Share for the three months ended in Sep. 2024 was $-0.50. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.97.

During the past 3 years, the average EBIT per Share Growth Rate was -44.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Fractyl Health's EBIT per Share or its related term are showing as below:

GUTS' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -44.9 Med: -31.55 Max: -18.2
Current: -44.9

During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Fractyl Health was -18.20% per year. The lowest was -44.90% per year. And the median was -31.55% per year.

GUTS's 3-Year EBIT Growth Rate is ranked worse than
88.08% of 1250 companies
in the Biotechnology industry
Industry Median: 2.8 vs GUTS: -44.90

Fractyl Health's EBIT for the three months ended in Sep. 2024 was $-23.79 Mil.

Fractyl Health EBIT per Share Historical Data

The historical data trend for Fractyl Health's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fractyl Health EBIT per Share Chart

Fractyl Health Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

-0.36

-0.35

-0.78

-0.60

-1.07

Fractyl Health Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Jun21	Sep21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT per Share	Get a 7-Day Free Trial												-0.29	-0.27	-0.72	-0.48	-0.50

Fractyl Health EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Fractyl Health's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-50.836	/	47.607
=	-1.07

Fractyl Health's EBIT per Share for the quarter that ended in Sep. 2024 is calculated as

	EBIT per Share		(Q: Sep. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-23.794	/	47.974
=	-0.50

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.97

Fractyl Health (NAS:GUTS) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Fractyl Health EBIT per Share Related Terms

Thank you for viewing the detailed overview of Fractyl Health's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Fractyl Health Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fractyl Health Inc (NAS:GUTS) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

3 Van de Graaff Drive, Suite 200, Burlington, MA, USA, 01803

Website

https://www.fractyl.com

Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.